GlassScriptPhysician profile
Aamir Husain
NPI 1902300429
$20,124.50
in general payments reported to CMS, 2019-2025
25 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $248 · 2023: $853 · 2024: $1,653 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $14K · Food and Beverage: $3,611 · Travel and Lodging: $1,645 · Education: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $14,000.00 |
| Food and Beverage | $3,611.39 |
| Travel and Lodging | $1,645.00 |
| Education | $620.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,310.00 | 2023-2025 | Tacticath, Assurity, Ensite |
| Medtronic, INC. | $5,433.12 | 2022-2025 | Micra, Cobalt Dr Mri Surescan, Claria Mri Quad Crt-D Surescan |
| Boston Scientific Corporation | $2,519.04 | 2022-2025 | General - Therapies, Accolade Sr, Resonate El Icd Vr |
| Novartis Pharmaceuticals Corporation | $764.29 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.71 | 2022-2024 | Lifevest |
| Atricure, INC. | $178.43 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Pfizer INC. | $177.21 | 2024-2025 | |
| Edwards Lifesciences Corporation | $173.95 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cardiva Medical, INC. | $157.58 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Shockwave Medical, INC | $155.40 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Janssen Pharmaceuticals, INC | $151.06 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.47 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $112.92 | 2023-2025 | Camzyos |
| Abiomed | $90.78 | 2025 | |
| Biosense Webster, INC. | $87.46 | 2025 | Carto 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $82.34 | 2025 | |
| Merck Sharp & Dohme LLC | $82.27 | 2023-2024 | Verquvo |
| Amgen INC. | $74.88 | 2023-2024 | Repatha |
| Becton, Dickinson and Company | $44.19 | 2024 | Hemosphere |
| Bayer Healthcare Pharmaceuticals INC. | $33.35 | 2025 | |
| Penumbra, INC. | $32.38 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.70 | 2023-2024 | Farxiga |
| Terumo Medical Corporation | $23.98 | 2022 | |
| United Therapeutics Corporation | $20.33 | 2024 | |
| Chiesi USA, INC. | $16.66 | 2024 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.